

## 1 **Impact of Fludrocortisone on the Outcomes of Subarachnoid Hemorrhage Patients: A** 2 **Retrospective Analysis**

3 Akshittkumar M. Mistry, MD<sup>1</sup>; Janki Naidugari, BS;<sup>2</sup> Michael J. Feldman, MD<sup>3</sup>; Jordan A.  
4 Magarik, MD, MS<sup>3</sup>; Dale Ding, MD<sup>1</sup>; Isaac J. Abecassis, MD;<sup>1</sup> Matthew W. Semler, MD, MSc;<sup>4</sup>  
5 Todd W. Rice, MD, MSc<sup>4</sup>

6  
7 <sup>1</sup>Department of Neurosurgery, University of Louisville, Louisville, KY, USA; <sup>2</sup>School of Medicine,  
8 University of Louisville, Louisville, KY, USA; <sup>3</sup>Department of Neurosurgery, Vanderbilt University  
9 Medical Center, Nashville, TN, USA; <sup>4</sup>Department of Medicine, Division of Allergy, Pulmonary,  
10 and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

### 11 12 **Corresponding Author:**

13 Akshittkumar M. Mistry, MD  
14 Department of Neurological Surgery, 220 Abraham Flexner Way, 15th Floor,  
15 University of Louisville, Louisville, KY 40202  
16 Telephone: 502-407-3226; Fax: 502-582-7477; E-mail: [axitamm@gmail.com](mailto:axitamm@gmail.com)

17  
18 **Funding:** was provided by the Vanderbilt Institute for Clinical and Translational Research  
19 (UL1TR000445 and UL1TR002243 from NCATS/NIH).

20 **Short title:** Fludrocortisone improves SAH outcomes

21 **Keywords:** Subarachnoid hemorrhage; Fludrocortisone; Critical Care; Mineralocorticoid

22  
23 **Disclosures:** Isaac Abecassis has the following disclosures: 1) Remedy Robotics: Consultant,  
24 Equity. 2) IschemaView Inc/Rapid AI: Clinical consultant. 3) Rapid Medical: Consultant. 4) Balt:  
25 Consultant. 5) CNS Foundation: Grant Research Support.

26 **ABSTRACT**

27 **Background:** Whether the use of fludrocortisone affects outcomes of patients with aneurysmal  
28 subarachnoid hemorrhage (aSAH) and its usage rate in the United States remain unknown.

29 **Methods:** We conducted a retrospective analysis of 78 consecutive patients with a ruptured  
30 aSAH at a single academic center in the United States. The primary outcome was the score on  
31 the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. We adjusted  
32 the primary outcome for age, hypertension, aSAH grade, and time from aSAH onset to  
33 aneurysm treatment. Secondary outcomes were brain and cardiopulmonary dysfunction events.

34 **Results:** Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5];  
35 64% were female, and 41 (53%) received fludrocortisone. The adjusted common odds ratio,  
36 aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95%  
37 CI, 0.14-0.80; P=0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction  
38 events were not statistically different: delayed cerebral ischemia (22% vs. 39%, P=0.16);  
39 cardiac dysfunction (0% vs. 11%; P=0.10); and pulmonary edema (15% vs. 8%; P=0.59).

40 **Conclusions:** The risk of disability or death at 90 days was lower with the use of fludrocortisone  
41 in aSAH patients.

42

## 43 INTRODUCTION

44 Inpatient and overall mortality of patients with aneurysmal subarachnoid hemorrhage  
45 (aSAH) are 20% (1-3) and 40%, respectively (4). The high morbidity and mortality result from  
46 life-threatening neurological sequelae like re-hemorrhage, cerebral swelling, and vasospasm,  
47 which leads to ischemic strokes, as well as non-neurological complications like fatal volume loss  
48 from cerebral salt wasting (kidney-driven natriuresis), acute kidney injury (AKI), and  
49 cardiopulmonary injury (5-7).

50 Patients with aSAH can have fatal polyuria (>4 liters/day) from natriuresis (8, 9). Thus,  
51 they require incredibly large volumes of intravenous fluids to maintain their intravascular volume  
52 (8-10). Hence, fluid therapy is the most common therapy aSAH patients receive. In the  
53 presence of natriuresis-driven polyuria, fluid administration is among the most considerable  
54 challenges in the medical management of aSAH patients. Failure to do so can compromise  
55 multi-organ perfusion, increasing the risk of life-threatening ischemic strokes, cardiopulmonary  
56 dysfunction, and AKI (11).

57 Fludrocortisone is well-known to reduce natriuresis and hyponatremia, but its effects on  
58 outcomes in aSAH patients have not been studied. Using data from a prospective study and two  
59 phase 2 randomized controlled trials, we have shown that fludrocortisone decreases natriuresis,  
60 hyponatremia, and polyuria in aSAH patients, leading to lower fluid and sodium requirements  
61 and hypovolemic incidences (8). Importantly, a meta-analysis of the studies shows that it lowers  
62 the rate of symptomatic vasospasm (8). The 2023 American Heart Association aSAH guidelines  
63 recommend that “the use of mineralocorticoids is reasonable to treat natriuresis and  
64 hyponatremia” (12).

65 However, the impact of fludrocortisone on the clinical outcomes of aSAH patients has  
66 yet to be studied. Therefore, to fill this knowledge gap, we conducted a retrospective analysis of  
67 aSAH patients enrolled in the SMART randomized trial,(13) comparing outcomes of patients

68 treated with fludrocortisone with those not treated with fludrocortisone. We hypothesized that,  
69 because of the established efficacy of fludrocortisone, its use would result in less death or  
70 disability, as measured by the modified Rankin Scale (14) (mRS), at 90 days.

71

## 72 **METHODS**

### 73 **Study Design and Patient Selection**

74 We conducted a retrospective cohort analysis of all aSAH patients enrolled in the  
75 Isotonic Solutions and Major Adverse Renal Events Trial (SMART)(13) after its results and data  
76 of aSAH patients were available. SMART was a pragmatic, unblinded, cluster-randomized,  
77 multiple-crossover clinical trial (ClinicalTrials.gov: NCT02444988, NCT02547779) conducted at  
78 an academic medical center in the United States between June 1, 2015, and April 30, 2017.  
79 Trial protocol did not control the use of fludrocortisone. This subanalysis was approved by the  
80 institutional review board at Vanderbilt University Medical Center (IRB # 141349).

81

### 82 **Data Collection**

83 Data for aSAH patients were collected retrospectively blinded to fludrocortisone use. The  
84 following co-variables were collected: past medical history (hypertension, diabetes, ischemic  
85 heart disease, tobacco use, and prior aSAH); aSAH severity as measured on Hunt and Hess  
86 scale, the World Federation of Neurological Surgeons (WFNS) grading system, and the  
87 modified Fischer scale; location, largest linear measurement, and treatment procedure  
88 (endovascular embolization vs. clip obliteration) of the ruptured aneurysm; time from symptom  
89 onset to procedural intervention; new stroke (iatrogenic or spontaneous aneurysmal re-rupture);  
90 development of hydrocephalus requiring ventricular cerebrospinal fluid drainage; and infection  
91 of the central nervous system, meninges, or cerebrospinal fluid (microbiologically proven or  
92 clinical signs treated empirically with 4 or more consecutive days of antibiotics).

93

#### 94 **Study Intervention: Fludrocortisone Administration**

95           The general institutional practice was to maintain euvolemia in aSAH patients and treat  
96 electrolyte imbalances. There was no institutional protocol to maintain euvolemia and treat  
97 hyponatremia. The use of fludrocortisone (dosage regimen and length), enteral salt, and/or  
98 hypertonic saline was provider dependent. Fludrocortisone was frequently initiated in patients  
99 with vasospasm who were at risk of hypovolemia. In this cohort, fludrocortisone was started as  
100 early as the 3<sup>rd</sup> day of ICU admission and maintained for the majority of ICU stay.

101

#### 102 **Study Outcomes**

103           Our study outcomes were not part of the SMART trial. Our primary outcome was the  
104 ordinal score on the mRS (14) (range, 0 [no symptoms] to 6 [death]) around 90 days. It was  
105 collected prospectively as part of routine clinical follow-up. Secondary outcomes included:

- 106           • the 21-day incidence of symptomatic vasospasm (defined as at least a 2-point  
107 decrease in Glasgow coma score or 2-point increase in the motor score of the  
108 National Institutes of Health Stroke Scale lasting for at least 8 hours after  
109 exclusion of attributable cerebral and non-cerebral conditions) and delayed  
110 cerebral ischemia (defined as a presence of a new, post-operative hyperintensity  
111 on diffusion-weighted magnetic resonance imaging, or a new, permanent focal  
112 neurological deficit, or a permanent decrease on Glasgow coma score of at least  
113 2 points unattributable to other cerebral and non-cerebral conditions); (15, 16)
- 114           • total amount of fludrocortisone, enteral sodium chloride, and hypertonic saline  
115 (3% sodium chloride) received during the hospitalization;
- 116           • cardiac dysfunction defined as myocardial infarction, new onset of heart failure,  
117 or initiation of inotropic therapy;

- 118                   • pulmonary edema evidenced by a chest radiograph or diuretic treatment with the  
119                   goal of treating pulmonary edema.

120

## 121 **Statistical Analysis**

122                   Chi-square test for categorical data and the Wilcoxon test for continuous data were  
123                   utilized for between-group comparisons without adjustment for covariates. The primary analysis  
124                   compared 90-day mRS scores treated as an ordinal variable between patients treated with and  
125                   without fludrocortisone using a proportional odds regression model, adjusting for age, history of  
126                   hypertension, time from aSAH onset to aneurysm treatment, procedure received (clip or  
127                   embolization), and the WFNS grade at baseline. This outcome was not assessed at the 90-day  
128                   timepoint in 6 patients; thus for them, the last known mRS score was carried forward. To assess  
129                   the robustness of the primary analysis, we performed three sensitivity analyses in which we  
130                   repeated the primary analysis: 1) excluding patients with missing 90-day mRS scores; 2)  
131                   substituting the mRS scores with values imputed using multivariate imputation by chained  
132                   equations (mice v3.11 and mitools v2.4 R packages) in which one hundred different datasets  
133                   were generated with imputed values and results were pooled; 3) any co-variable correlated with  
134                   fludrocortisone was introduced into the model to adjust its effects; and 4) intervention tested in  
135                   the SMART trial. The results of the regression models are presented with a point estimate odds  
136                   ratio and associated 95% confidence interval (CI) range. Significance was set at a two-tailed  $\alpha$   
137                    $\leq 0.05$ . All analyses were performed using R version 4.0.2 software (R Foundation for Statistical  
138                   Computing, Vienna, Austria).

139

## 140 **RESULTS**

### 141 **Baseline Patient Characteristics**

142 The median age of the 78 aSAH patients included in this study was 58 years  
143 (interquartile range, IQR, 49 to 64.5) and 50 patients (64%) were female. A total of 70 patients  
144 (90%) received an endovascular embolization of their ruptured aneurysm, 46 (59%) of which  
145 were in the anterior cerebral circulation. Forty-one patients (53%) were treated with  
146 fludrocortisone and 37 patients (47%) were not treated with fludrocortisone. Besides age, which  
147 was lower in the group treated with fludrocortisone, the two groups were similar at baseline  
148 (Table 1).

149 In the group that received fludrocortisone, the median dosage and the number of  
150 patients treated per ICU admission day are plotted in Figure 1. More patients treated with  
151 fludrocortisone were also co-treated with enteral salt [13 (32%) vs. 6 (16%);  $P=0.12$ ] and  
152 hypertonic saline [23 (56%) vs. 6 (16%);  $P<0.01$ ]. When used, the amount of enteral salt and  
153 hypertonic saline did not significantly differ between groups (Table 2).

154

## 155 **Outcomes**

156 Compared with patients who did not receive fludrocortisone, patients who received  
157 fludrocortisone experienced a lower mRS scores at 90 days (adjusted common odds ratio, aOR,  
158 of 0.33; 95% CI, 0.14 to 0.80;  $P=0.02$ ), with values below 1.0 favoring receipt of fludrocortisone  
159 (Figure 2; Table 3). Excluding the 6 patients who did not have a mRS score at 90 days resulted  
160 in an aOR of 0.36 (95% CI, 0.14 to 0.92;  $P=0.03$ ). Substituting them with imputed values  
161 resulted in an aOR of 0.36 (95% CI, 0.14 to 0.91;  $P=0.04$ ). Because the use of enteral salt and  
162 hypertonic saline correlated with the use of fludrocortisone (Table 3), we introduced these  
163 variables in the regression model. Both did not independently correlate with the outcomes (use  
164 of enteral salt aOR 0.5 [0.18-1.35];  $P=0.17$ ; and use of hypertonic saline aOR 1.30 [0.45-3.70];  
165  $P=0.63$ ), but the use of fludrocortisone maintained a similar association as in the primary  
166 analysis (aOR 0.41 [0.15-1.04];  $P=0.06$ ). Because these patients were enrolled in the SMART

167 trial, comparing the primary use of balanced crystalloids to saline for intravenous fluid therapy,  
168 we included the trial fluid assignment as an interaction variable in the model. Of the 41 patients  
169 who received fludrocortisone, 21 were assigned saline and 20 were assigned a balanced  
170 crystalloid; and of the 37 patients who did not receive fludrocortisone, 20 were assigned saline  
171 and 17 were assigned a balanced crystalloid. In this model, the use of fludrocortisone continued  
172 to maintain a similar association as in the primary analysis (aOR 0.15 [0.04-0.60]; P=0.01). The  
173 use of saline was associated with better outcomes (aOR 0.24 [0.06-0.96]; P=0.05). Importantly,  
174 in the model the interaction term of fluid assignment and fludrocortisone did not associate with  
175 outcome (aOR 3.22 [0.50-21.6]; P=0.22).

176 Patients treated with or without fludrocortisone experienced similar incidences of organ  
177 dysfunction events (Table 4). Patients treated with fludrocortisone had higher but not statistically  
178 significant incidences of symptomatic vasospasm [17 (42%) vs 8 (22%); P=0.10], delayed  
179 cerebral ischemia events [17 (42%) vs 8 (22%); P=0.16], and pulmonary edema [6 (15%) vs 3  
180 (8%); P=0.59]. No patient with fludrocortisone had cardiac dysfunction (0 (0%) vs 4 (11%);  
181 P=0.10). Length of hospital stay did not differ with the use of fludrocortisone (median 17 days  
182 [IQR 14-22] vs 16 [11-20]; Table 4).

183

## 184 **DISCUSSION**

185 The 2023 American Heart Association aSAH guidelines recommend that “the use of  
186 mineralocorticoids is reasonable to treat natriuresis and hyponatremia,”(12) citing its efficacy  
187 from randomized controlled trials (8). Natriuresis-driving hypovolemia can compromise organ  
188 perfusion, risking life-threatening ischemic strokes (in the setting of cerebral vasospasm), AKI,  
189 and cardiopulmonary dysfunction (11). Indeed, a meta-analysis showed that fludrocortisone  
190 reduces symptomatic vasospasm in aSAH patients (8). A 8346-patient population-based study  
191 showed that poor hemodynamic status (hyponatremia and hypovolemia) increases the risk of



192 adverse events from vasospasm (17) resulting in poor outcomes. A similar therapeutic effect of  
193 fludrocortisone has been observed in patients with TB meningitis who also exhibit natriuresis-  
194 driven hypovolemia and strokes (18). However, its impact on outcomes of aSAH patients is  
195 unclear and has not been reported since 1999 (19). In this retrospective study, we found that  
196 fludrocortisone therapy was independently associated with better outcomes following aSAH.

197         The results of our study must be interpreted within its limitations. First, this study has  
198 inherent retrospective bias. Second, the effect size we observed is large and may be due to the  
199 study's small sample size. The sample size was selected based on the identification and  
200 selection of a *consecutive* cohort of aSAH patients, which was facilitated by the SMART trial.  
201 Third, conduct at a single center limits generalizability. Fourth, fludrocortisone was not  
202 protocolized and was often started by some providers after the patient exhibited symptomatic  
203 vasospasm and hypovolemia, weakening any causal link between the outcomes and  
204 fludrocortisone. Thus, the higher rate of symptomatic vasospasm and delayed cerebral ischemia  
205 seen in the group treated with fludrocortisone should be interpreted with great caution. All prior  
206 studies, including randomized controlled trials, have shown fludrocortisone is associated with  
207 lower incidences of symptomatic vasospasm and delayed cerebral ischemia (8). However, it is  
208 noteworthy that despite greater incidences of symptomatic vasospasm and delayed cerebral  
209 ischemia, the use of fludrocortisone in these patients was associated with better outcomes. Our  
210 results must be confirmed with prospective randomized controlled trials.

211

## 212 **CONCLUSIONS**

213         In this retrospective cohort analysis, the use of fludrocortisone was associated with  
214 better outcomes in aSAH patients. This finding must be confirmed with a randomized controlled  
215 trial.

216

217 **REFERENCES**

- 218 1. Chan V, Lindsay P, McQuiggan J, et al. Declining Admission and Mortality Rates for  
219 Subarachnoid Hemorrhage in Canada Between 2004 and 2015. *Stroke* 2019;50:181-184.
- 220 2. Lee VH, Ouyang B, John S, et al. Risk stratification for the in-hospital mortality in  
221 subarachnoid hemorrhage: the HAIR score. *Neurocrit Care* 2014;21:14-19.
- 222 3. Stienen MN, Germans M, Burkhardt JK, et al. Predictors of In-Hospital Death After  
223 Aneurysmal Subarachnoid Hemorrhage: Analysis of a Nationwide Database (Swiss SOS [Swiss  
224 Study on Aneurysmal Subarachnoid Hemorrhage]). *Stroke* 2018;49:333-340.
- 225 4. Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid  
226 haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol*  
227 2009;8:635-642.
- 228 5. Chen S, Li Q, Wu H, et al. The harmful effects of subarachnoid hemorrhage on extracerebral  
229 organs. *Biomed Res Int* 2014;2014:858496.
- 230 6. Lantigua H, Ortega-Gutierrez S, Schmidt JM, et al. Subarachnoid hemorrhage: who dies, and  
231 why? *Crit Care* 2015;19:309.
- 232 7. Solenski NJ, Haley EC, Jr., Kassell NF, et al. Medical complications of aneurysmal  
233 subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants  
234 of the Multicenter Cooperative Aneurysm Study. *Crit Care Med* 1995;23:1007-1017.
- 235 8. Mistry AM, Mistry EA, Ganesh Kumar N, et al. Corticosteroids in the Management of  
236 Hyponatremia, Hypovolemia, and Vasospasm in Subarachnoid Hemorrhage: A Meta-Analysis.  
237 *Cerebrovasc Dis* 2016;42:263-271.
- 238 9. Mistry AM, Magarik JA, Feldman MJ, et al. Saline versus Balanced Crystalloids for Adults  
239 with Aneurysmal Subarachnoid Hemorrhage: A Subgroup Analysis of the SMART Trial. *Stroke*  
240 *Vasc Interv Neurol* 2022;2.

- 241 10. Barlow B, Thompson Bastin ML, Shadler A, et al. Association of chloride-rich fluids and  
242 medication diluents on the incidence of hyperchloremia and clinical consequences in  
243 aneurysmal subarachnoid hemorrhage. *J Neurocrit Care* 2022;15:113-121.
- 244 11. Brown RJ, Epling BP, Staff I, et al. Polyuria and cerebral vasospasm after aneurysmal  
245 subarachnoid hemorrhage. *BMC Neurol* 2015;15:201.
- 246 12. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With  
247 Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart  
248 Association/American Stroke Association. *Stroke* 2023;54:e314-e370.
- 249 13. Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill  
250 Adults. *N Engl J Med* 2018;378:829-839.
- 251 14. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the  
252 assessment of handicap in stroke patients. *Stroke* 1988;19:604-607.
- 253 15. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after  
254 aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational  
255 studies: proposal of a multidisciplinary research group. *Stroke* 2010;41:2391-2395.
- 256 16. Rosengart AJ, Schultheiss KE, Tolentino J, et al. Prognostic factors for outcome in patients  
257 with aneurysmal subarachnoid hemorrhage. *Stroke* 2007;38:2315-2321.
- 258 17. Rumalla K, Lin M, Ding L, et al. Risk Factors for Cerebral Vasospasm in Aneurysmal  
259 Subarachnoid Hemorrhage: A Population-Based Study of 8346 Patients. *World neurosurgery*  
260 2021;145:e233-e241.
- 261 18. Misra UK, Kalita J, Kumar M. Safety and Efficacy of Fludrocortisone in the Treatment of  
262 Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial.  
263 *JAMA Neurol* 2018;75:1383-1391.

264 19. Mori T, Katayama Y, Kawamata T, et al. Improved efficiency of hypervolemic therapy with  
265 inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid  
266 hemorrhage. J Neurosurg 1999;91:947-952.

267

268 **Table 1. Patient characteristics at baseline.**  
269

Patient characteristics <sup>a</sup>	No Fludrocortisone (n=37)	Fludrocortisone (n=41)	P value <sup>b</sup>
Age, median [IQR], yrs	61 [53-67]	55 [49-62]	0.04
Men, n (%)	12 (32%)	17 (42%)	0.56
Chronic comorbidities, n (%)			
Ischemic heart disease	2 (5%)	5 (12%)	0.52
Active tobacco smoking	12 (32%)	20 (49%)	0.22
Hypertension	31 (84%)	29 (71%)	0.27
Diabetes	5 (14%)	3 (7%)	0.60
Prior subarachnoid hemorrhage	2 (5%)	0 (0%)	0.43
Subarachnoid hemorrhage severity			
WFNS grade			0.72
Grade 1	7 (19%)	12 (29%)	
Grade 2	10 (27%)	12 (29%)	
Grade 3	3 (8%)	4 (10%)	
Grade 4	9 (24%)	6 (15%)	
Grade 5	8 (22%)	7 (17%)	
Hunt Hess score			0.47
Grade 1	0 (0%)	0 (0%)	
Grade 2	11 (30%)	14 (34%)	
Grade 3	9 (24%)	15 (37%)	
Grade 4	11 (30%)	8 (20%)	
Grade 5	6 (16%)	4 (10%)	
modified Fischer score			0.56
Score 1	1 (3%)	1 (2%)	
Score 2	3 (8%)	7 (17%)	
Score 3	8 (22%)	11 (27%)	
Score 4	25 (68%)	22 (54%)	
Aneurysm location, n (%)			>0.99
Anterior circulation	22 (59%)	24 (59%)	
Posterior circulation	15 (41%)	17 (41%)	
Aneurysm size, median [IQR], mm	4.6 [4.0-6.4]	5.4 [4.0-8.2]	0.22
Treatments received			0.60
Clip obliteration, n (%)	5 (14%)	3 (7%)	
Endovascular embolization, n (%)	32 (86%)	38 (93%)	
Time from symptom onset to surgical treatment, median [IQR], days	1.46 [1.00-4.46]	1.54 [1.34-2.42]	0.82
CNS complications, n (%)			
Aneurysm re-rupture	1 (3%)	0 (0%)	0.96
Secondary open operation <sup>c</sup>	4 (11%)	0 (0%)	0.10
Iatrogenic stroke	3 (8%)	0 (0%)	0.20
Ventricular CSF diversion	24 (65%)	30 (73%)	0.58
CNS infection <sup>d</sup>	1 (3%)	4 (10%)	0.42

270 <sup>a</sup>Abbreviations: CSF – cerebrospinal fluid; CNS – central nervous system; ICU – intensive care  
271 unit; IQR – interquartile range; WFNS – world federation of neurological surgeons

272 <sup>b</sup>Statistical tests: Group differences were tested with a Chi-square test for categorical variables  
273 and Wilcoxon test for continuous variables.

274 <sup>c</sup>Secondary open operation defined as craniotomy or craniectomy after completion for treatment  
275 of the aneurysm.

276 <sup>d</sup>CNS infection defined as infection of the central nervous system, meninges, or cerebrospinal  
277 fluid (microbiologically proven or clinical signs treated empirically with 4 or more consecutive  
278 days of antibiotics).

279 **Table 2. Sodium supplementation between ICU admission and day 14 in aSAH patients**  
280 **treated with and without fludrocortisone.**

281

<b>Sodium Replacement<sup>a</sup></b>	<b>Fludrocortisone (n=41)</b>	<b>No Fludrocortisone (n=37)</b>	<b>P value</b>
<b>Hypertonic saline</b>			
median [IQR], mL	4500 [1000-6000]	1625 [1062.50-5187.50]	0.79
n	13 (32%)	6 (16%)	0.12
<b>Enteral salt</b>			
median [IQR], g	14 [6-47.5]	11.5 [7.25-16.5]	0.40
n	23 (56%)	6 (16%)	<0.01

282 <sup>a</sup>Abbreviations: aSAH – aneurysmal subarachnoid hemorrhage; ICU – intensive care unit; IQR –  
283 interquartile range

284 **Table 3. Ordinal regression models for 90-day modified Rankin Scale (mRS) scores.**  
285 Adjusted common odds ratios with 95% confidence intervals and corresponding P values are  
286 reported.  
287

Co-variable	Effect size
Fludrocortisone (vs. no fludrocortisone)	0.33 [0.14-0.80], P=0.02
Age (continuous)	1.06 [1.02-1.10], P=0.01
Time to treatment (continuous)	1.00 [0.91-1.10], P=0.96
Hypertension (no hypertension as reference)	1.20 [0.44-3.31], P=0.72
Endovascular embolization (clip obliteration as reference)	1.01 [0.21-4.80], P=0.99
World Federation of Neurological Surgeon's grade (Grade 1 as reference)	
Grade 2	2.27 [0.67-7.88], P=0.19
Grade 3	4.70 [0.92-24.7], P=0.06
Grade 4	5.36 [1.50-20.2], P=0.01
Grade 5	18.7 [4.78-79.0], P<0.01

288



289 **Table 4. Outcomes**  
290

<b>Outcome<sup>a</sup></b>	<b>No Fludrocortisone (n=37)</b>	<b>Fludrocortisone (n=41)</b>	<b>Adjusted common odds ratio (95% CI)</b>	<b>P value<sup>c</sup></b>
<b>Primary outcome</b>				
mRS at 90 days, <i>n</i>	3 [2-4]	1 [1-2]	0.33 [0.14-0.80] <sup>b</sup>	0.02
<b>Secondary outcomes</b>				
<i>Clinical outcomes, n (%)</i>				
Length of stay, days	16 [11-20]	17 [14-22]		0.39
<i>Adverse organ-based events, n (%)</i>				
Symptomatic vasospasm	8 (22%)	17 (42%)	-	0.10
Delayed cerebral ischemia	8 (22%)	16 (39%)	-	0.16
Pulmonary edema <sup>d</sup>	3 (8%)	6 (15%)	-	0.59
Cardiac dysfunction <sup>e</sup>	4 (11%)	0 (0%)	-	0.10

291 <sup>a</sup>Abbreviations: CI – confidence interval; mRS – modified Rankin Scale

292 <sup>b</sup>Adjusted common odds ratio from a proportional odds regression analysis

293 <sup>c</sup>Group differences were tested with a Chi-square test for categorical variables and Wilcoxon  
294 test for continuous variables; if odds ratios are presented, associated P values are presented

295 <sup>d</sup>Pulmonary edema evidenced by a chest radiograph and/or initiation of a diuretic treatment with  
296 the goal of treating pulmonary edema.

297 <sup>e</sup>Cardiac dysfunction defined as myocardial infarction, new onset of heart failure, or initiation of  
298 inotropic therapy.


299 **FIGURE LEGENDS**

300 **Figure 1. Fludrocortisone use in aneurysmal subarachnoid hemorrhage patients.** The  
301 median dose of fludrocortisone (blue line) with interquartile range (light blue shade) and the  
302 number of patients treated with fludrocortisone (red line) are plotted against the post-  
303 subarachnoid hemorrhage day.

304

305

306 **Figure 2. Functional outcomes of patients with aneurysmal subarachnoid hemorrhage**  
307 **treated with and without fludrocortisone.** Distribution of scores on the modified Rankin scale  
308 (mRS) at 90 days according to the treatment with fludrocortisone. The mRS ranges from a score  
309 of 0, indicating no symptoms, to a score of 6, indicating death. The numbers within the bars are  
310 percentages of patients who attained the score.



90-day mRS 0 1 2 3 4 5 6

